Search Results

You are looking at 131 - 140 of 1,415 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy

Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl

Background Ovarian clear cell carcinoma (OCCC) is a rare subtype of epithelial ovarian malignancy (EOM), accounting for approximately 5% to 10% of all EOMs in North America. 1 – 3 Advanced OCCC portends poor prognosis, which is often attributed to

Full access

Importance of Family History of Colorectal Carcinoma In Situ Versus Invasive Colorectal Cancer: A Nationwide Cohort Study

Yu Tian, Elham Kharazmi, Hermann Brenner, Xing Xu, Kristina Sundquist, Jan Sundquist, and Mahdi Fallah

Background Colorectal cancer (CRC) has become the third most common cancer and the second leading cause of cancer death globally. 1 Colorectal carcinoma in situ (CCIS), which is defined as abnormal cells in the mucosa (innermost layer) of the

Full access

Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib

Vaia Florou, Christopher Nevala-Plagemann, Jonathan Whisenant, Patricia Maeda, Glynn W. Gilcrease, and Ignacio Garrido-Laguna

The mammary analog secretory carcinomas (MASCs) of the salivary gland were first described in 2010 by Skálová et al. 1 The nomenclature of MASC was proposed because of the histologic and immunohistochemical similarities with the secretory

Full access

Updates to the Management of Kidney Cancer

Eric Jonasch

“It is a very exciting time in renal cell carcinoma, with new treatments. Most of which are for clear cell carcinoma,” said Eric Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer

Full access

Mode of Detection of Second Breast Cancers in Patients Undergoing Surveillance After Treatment of Ductal Carcinoma in Situ

Bethany T. Waites, Liisa Lyon, Gillian Kuehner, Patience Odele, Laurel A. Habel, and Raymond Liu

Background More than 300,000 breast cancers are diagnosed in the United States annually. 1 Ductal carcinoma in situ (DCIS) accounts for 25% of newly diagnosed breast cancers and is treated surgically with additional radiation and hormone

Full access

CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience

Hinda Boutrid, Maryam Lustberg, Jeffrey Vandeusen, Sagar Sardesai, Daniel Stover, Robert Wesolowski, Mathew Cherian, Julie Stephens, Marilly Palettas, Evan Morgan, Mohmoud Kassem, Michael Berger, Craig A. Vargo, Bhuvaneswari Ramaswamy, and Nicole Williams

Background: Invasive lobular carcinoma (ILC) accounts for 5%–15% of all invasive breast cancer cases. ILC has the propensity for distant late recurrence with widespread metastatic disease. To our knowledge, there is limited data on the clinical

Full access

Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs

Vivek Narayan, Tao Liu, Yunjie Song, Joshua Mitchell, JoRean Sicks, Ilana Gareen, Lova Sun, Srinivas Denduluri, Ciaran Fisher, Jesse Manikowski, Mark Wojtowicz, Joseph Vadakara, Naomi Haas, Kenneth B. Margulies, and Bonnie Ky

systemic treatment approach for patients with advanced renal cell carcinoma (RCC) and thyroid cancer (TC), which represent the most common prescription indications. Indeed, prolonged VEGFR signaling inhibition with VEGFR TKIs is commonly used for several

Full access

Mortality After Invasive Second Breast Cancers Following Prior Radiotherapy for DCIS

Puyao C. Li, Zilu Zhang, Angel M. Cronin, and Rinaa S. Punglia

Background Women with a history of ductal carcinoma in situ (DCIS) are at increased risk for developing a second breast cancer (SBC) in either the ipsilateral or contralateral breast. 1 , 2 Many women receive breast-conserving surgery (BCS) with

Full access

Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines

Angela Pecoraro, Giuseppe Rosiello, Stefano Luzzago, Marina Deuker, Franciska Stolzenbach, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Anil Kapoor, Cristian Fiori, Francesco Porpiglia, and Pierre I. Karakiewicz

data can provide further detail regarding the distribution of patient and renal cell carcinoma (RCC) characteristics within this special patient group. Based on these considerations, we reexamined patients with RCC with T1a 0- to 2-cm renal tumors to

Full access

Merkel Cell Carcinoma Clinical Practice Guidelines in Oncology

Merkel cell carcinoma (MCC) is an aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer along with the regional and distant metastatic rates of thick melanoma. MCC has a mortality rate that exceeds that of melanoma. MCC is a rare tumor; therefore, no prospective, statistically significant data are available to verify the validity of any prognostic features or treatment outcomes. The panel relied on trends that are documented in smaller, individual studies and meta-analyses as well as their own collective experiences in developing these guidelines.

For the most recent version of the guidelines, please visit NCCN.org